Viral Vector & Plasmid DNA Manufacturing Market Report: Trends, Forecast and Competitive Analysis
Get it in 2 to 4 weeks by ordering today
The future of the viral vector & plasmid DNA manufacturing market looks promising with opportunities in antisense & RNAi, gene therapy, cell therapy, and vaccinology. The global viral vector & plasmid DNA manufacturing market is expected to grow with a CAGR of 14%-16% from 2020 to 2025. The major drivers for this market are technological advancements to mitigate challenges posed by conventional methods of vector production, increase in the number of clinical studies, and a growing number of gene therapy cases.
A total of XX figures / charts and XX tables are provided in this more than 150 pages report to help in your business decisions. Sample figures with some insights are shown below. To learn the scope, benefits, companies researched, and other details of the global viral vector & plasmid DNA manufacturing market report, please download the report brochure.
In this market, viral vector is the largest product segment of viral vector & plasmid DNA manufacturing, whereas pharmaceutical and biopharmaceutical companies is the largest end user. Growth in various segments of the viral vector & plasmid DNA manufacturing market are given below:
The study includes trends and forecast for the global viral vector & plasmid DNA manufacturing market by product, workflow, application, end use, disease, and region as follows:
By Product [Value ($ Million) shipment analysis for 2014 – 2025]:
Lucintel forecasts that viral vector will remain the largest product segment over the forecast period due to necessity and applicability of this product in different research interventions.
Within this market, pharmaceutical and biotechnology companies will remain the largest end use segment over the forecast period due to continuous introduction of advanced therapies coupled with a subsequent increase in the number of gene therapy-based discovery programs by companies.
North America will remain the largest region over the forecast period due to the fact that the United States has been a major destination for all the recent advancements in the field of medicine. Increasing investments in gene therapy products in the United States have led to the growth of the market studied in recent years. In the United States, regulatory encouragement and patient advocacy have pushed rare disease clinical research to the center stage.
Features of the Global Viral Vector & Plasmid DNA Manufacturing Market
Q.1 What are some of the most promising potential, high-growth opportunities for the global viral vector & plasmid DNA manufacturing market by products (viral vector, plasmid DNA, and non viral vector), workflow (upstream processing and downstream processing), application (antisense & RNAi, gene therapy, cell therapy, and vaccinology), end-use (pharmaceutical and biopharmaceutical companies and research institutes), disease (cancer, genetic disorders, infectious diseases, and others), and region (North America, Europe, Asia Pacific, and Rest of the World)?Q.2 Which segments will grow at a faster pace and why?
Q.3 Which region will grow at a faster pace and why?
Q.4 What are the key factors affecting market dynamics? What are the drivers and challenges of the global viral vector & plasmid DNA manufacturing market?
Q.5 What are the business risks and threats to the global viral vector & plasmid DNA manufacturing market?
Q.6 What are the emerging trends in this global viral vector & plasmid DNA manufacturing market and the reasons behind them?
Q.7 What are some changing demands of customers in this global viral vector & plasmid DNA manufacturing market?
Q.8 What are the new developments in this global viral vector & plasmid DNA manufacturing market? Which companies are leading these developments?
Q.9 Who are the major players in this global viral vector & plasmid DNA manufacturing market? What strategic initiatives are being implemented by key players for business growth?
Q.10 What are some of the competitive products and processes in this global viral vector & plasmid DNA manufacturing market, and how big of a threat do they pose for loss of market share via material or product substitution?
Q.11 What M&A activities did take place in the last five years in the global global viral vector & plasmid DNA manufacturing market?
Report Details
Key Features Description
Base Year for Estimation 2019
Trend Period
(Actual Estimates) 2014-2019
Forecast Period 2020-2025
Pages More than 150
Market Representation / Units Revenue in US $ Million
Report Coverage Market Trends & Forecasts, Competitor Analysis, New Product Development, Company Expansion, Merger, Acquisitions & Joint Venture, and Company Profiling
Market Segments Products (Viral Vector, Plasmid DNA, and Non Viral Vector), Workflow (Upstream Processing and Downstream Processing), Application (Antisense & Rnai, Gene Therapy, Cell Therapy, and Vaccinology), End-Use (Pharmaceutical and Biopharmaceutical Companies and Research Institutes), and Disease (Cancer, Genetic Disorders, Infectious Diseases, and Others)
Regional Scope North America (USA, Mexico, and Canada), Europe (United Kingdom, Spain, Germany, and France), Asia (China, India, and Japan), and ROW (Brazil)
Customization 10% Customization without Any Additional Cost
The future of the viral vector & plasmid DNA manufacturing market looks promising with opportunities in antisense & RNAi, gene therapy, cell therapy, and vaccinology. The global viral vector & plasmid DNA manufacturing market is expected to grow with a CAGR of 14%-16% from 2020 to 2025. The major drivers for this market are technological advancements to mitigate challenges posed by conventional methods of vector production, increase in the number of clinical studies, and a growing number of gene therapy cases.
A total of XX figures / charts and XX tables are provided in this more than 150 pages report to help in your business decisions. Sample figures with some insights are shown below. To learn the scope, benefits, companies researched, and other details of the global viral vector & plasmid DNA manufacturing market report, please download the report brochure.
In this market, viral vector is the largest product segment of viral vector & plasmid DNA manufacturing, whereas pharmaceutical and biopharmaceutical companies is the largest end user. Growth in various segments of the viral vector & plasmid DNA manufacturing market are given below:
The study includes trends and forecast for the global viral vector & plasmid DNA manufacturing market by product, workflow, application, end use, disease, and region as follows:
By Product [Value ($ Million) shipment analysis for 2014 – 2025]:
- Viral Vector
- Plasmid DNA
- Non Viral Vector
- Upstream Processing
- Downstream Processing
- Antisense & RNAi
- Gene Therapy
- Cell Therapy
- Vaccinology
- Pharmaceutical and Biopharmaceutical Companies
- Research Institutes
- Cancer
- Genetic Disorders
- Infectious Diseases
- Others
- North America
- United States
- Canada
- Mexico
- Europe
- United Kingdom
- Spain
- Germany
- France
- Asia Pacific
- China
- India
- Japan
- The Rest of the World
- Brazil
Lucintel forecasts that viral vector will remain the largest product segment over the forecast period due to necessity and applicability of this product in different research interventions.
Within this market, pharmaceutical and biotechnology companies will remain the largest end use segment over the forecast period due to continuous introduction of advanced therapies coupled with a subsequent increase in the number of gene therapy-based discovery programs by companies.
North America will remain the largest region over the forecast period due to the fact that the United States has been a major destination for all the recent advancements in the field of medicine. Increasing investments in gene therapy products in the United States have led to the growth of the market studied in recent years. In the United States, regulatory encouragement and patient advocacy have pushed rare disease clinical research to the center stage.
Features of the Global Viral Vector & Plasmid DNA Manufacturing Market
- Market Size Estimates: Global viral vector & plasmid DNA manufacturing market size estimation in terms of value ($M) shipment.
- Trend and Forecast Analysis: Market trends (2014-2019) and forecast (2020-2025) by various segments.
- Segmentation Analysis: Global viral vector & plasmid DNA manufacturing market size by various segments, such as product, workflow, application, end use, and disease in terms of value.
- Regional Analysis: Global viral vector & plasmid DNA manufacturing market breakdown by the North America, Europe, Asia Pacific, and Rest of the World.
- Growth Opportunities: Analysis of growth opportunities in different product, workflow, application, end use, disease, and region for the global viral vector & plasmid DNA manufacturing market.
- Strategic Analysis: This includes M&A, new product development, and competitive landscape of the global viral vector & plasmid DNA manufacturing market.
- Analysis of competitive intensity of the industry based on Porter’s Five Forces model.
Q.1 What are some of the most promising potential, high-growth opportunities for the global viral vector & plasmid DNA manufacturing market by products (viral vector, plasmid DNA, and non viral vector), workflow (upstream processing and downstream processing), application (antisense & RNAi, gene therapy, cell therapy, and vaccinology), end-use (pharmaceutical and biopharmaceutical companies and research institutes), disease (cancer, genetic disorders, infectious diseases, and others), and region (North America, Europe, Asia Pacific, and Rest of the World)?Q.2 Which segments will grow at a faster pace and why?
Q.3 Which region will grow at a faster pace and why?
Q.4 What are the key factors affecting market dynamics? What are the drivers and challenges of the global viral vector & plasmid DNA manufacturing market?
Q.5 What are the business risks and threats to the global viral vector & plasmid DNA manufacturing market?
Q.6 What are the emerging trends in this global viral vector & plasmid DNA manufacturing market and the reasons behind them?
Q.7 What are some changing demands of customers in this global viral vector & plasmid DNA manufacturing market?
Q.8 What are the new developments in this global viral vector & plasmid DNA manufacturing market? Which companies are leading these developments?
Q.9 Who are the major players in this global viral vector & plasmid DNA manufacturing market? What strategic initiatives are being implemented by key players for business growth?
Q.10 What are some of the competitive products and processes in this global viral vector & plasmid DNA manufacturing market, and how big of a threat do they pose for loss of market share via material or product substitution?
Q.11 What M&A activities did take place in the last five years in the global global viral vector & plasmid DNA manufacturing market?
Report Details
Key Features Description
Base Year for Estimation 2019
Trend Period
(Actual Estimates) 2014-2019
Forecast Period 2020-2025
Pages More than 150
Market Representation / Units Revenue in US $ Million
Report Coverage Market Trends & Forecasts, Competitor Analysis, New Product Development, Company Expansion, Merger, Acquisitions & Joint Venture, and Company Profiling
Market Segments Products (Viral Vector, Plasmid DNA, and Non Viral Vector), Workflow (Upstream Processing and Downstream Processing), Application (Antisense & Rnai, Gene Therapy, Cell Therapy, and Vaccinology), End-Use (Pharmaceutical and Biopharmaceutical Companies and Research Institutes), and Disease (Cancer, Genetic Disorders, Infectious Diseases, and Others)
Regional Scope North America (USA, Mexico, and Canada), Europe (United Kingdom, Spain, Germany, and France), Asia (China, India, and Japan), and ROW (Brazil)
Customization 10% Customization without Any Additional Cost
1. EXECUTIVE SUMMARY
2. MARKET BACKGROUND AND CLASSIFICATIONS
2.1: Introduction, Background, and Classifications
2.2: Supply Chain
2.3: Industry Drivers and Challenges
3. MARKET TRENDS AND FORECAST ANALYSIS FROM 2014 T 2025
3.1: Macroeconomic Trends and Forecast
3.2: Global Viral Vector & Plasmid DNA Manufacturing Market Trends and Forecast
3.3: Global Viral Vector & Plasmid DNA Manufacturing Market by Product
3.3.1: Viral Vector
3.3.2: Plasmid DNA
3.3.3: Non Viral Vector
3.4: Global Viral Vector & Plasmid DNA Manufacturing Market by Workflow
3.4.1: Upstream Processing
3.4.2: Downstream Processing
3.5: Global Viral Vector & Plasmid DNA Manufacturing Market by Application
3.5.1: Antisense & RNAi
3.5.2: Gene Therapy
3.5.3: Cell Therapy
3.5.4: Vaccinology Fish
3.6: Global Viral Vector & Plasmid DNA Manufacturing Market by End Use
3.6.1: Pharmaceutical and Biopharmaceutical Companies
3.6.2: Research Institutes
3.7: Global Viral Vector & Plasmid DNA Manufacturing Market by Disease
3.7.1: Cancer
3.7.2: Genetic Disorders
3.7.3: Infectious Diseases
3.7.4: Other
4. MARKET TRENDS AND FORECAST ANALYSIS BY REGION
4.1: Global Viral Vector & Plasmid DNA Manufacturing Market by Region
4.2: North American Viral Vector & Plasmid DNA Manufacturing Market
4.2.1: Market by Product: Viral Vector, Plasmid DNA, and Non Viral Vector,
4.2.2: Market by Workflow: Upstream Processing and Downstream Processing
4.2.3: Market by Application: Antisense & Rnai, Gene Therapy, Cell Therapy, and Vaccinology
4.2.4: Market by End-Use: Pharmaceutical and Biopharmaceutical Companies and Research Institutes
4.2.5: Market by Disease: Cancer, Genetic Disorders, Infectious Diseases, and Others
4.2.6: The United States Viral Vector & Plasmid DNA Manufacturing Market
4.2.7: The Canadian Viral Vector & Plasmid DNA Manufacturing Market
4.2.8: The Mexican Viral Vector & Plasmid DNA Manufacturing Market
4.3: European Viral Vector & Plasmid DNA Manufacturing Market
4.3.1: Market by Product: Viral Vector, Plasmid DNA, and Non Viral Vector,
4.3.2: Market by Workflow: Upstream Processing and Downstream Processing
4.3.3: Market by Application: Antisense & Rnai, Gene Therapy, Cell Therapy, and Vaccinology
4.3.4: Market by End-Use: Pharmaceutical and Biopharmaceutical Companies and Research Institutes
4.3.5: Market by Disease: Cancer, Genetic Disorders, Infectious Diseases, and Others
4.3.6: The United Kingdom Viral Vector & Plasmid DNA Manufacturing Market
4.3.7: The Spanish Viral Vector & Plasmid DNA Manufacturing Market
4.3.8: The German Viral Vector & Plasmid DNA Manufacturing Market
4.3.9: The French Viral Vector & Plasmid DNA Manufacturing Market
4.4: APAC Viral Vector & Plasmid DNA Manufacturing Market
4.4.1: Market by Product: Viral Vector, Plasmid DNA, and Non Viral Vector,
4.4.2: Market by Workflow: Upstream Processing and Downstream Processing
4.4.3: Market by Application: Antisense & Rnai, Gene Therapy, Cell Therapy, and Vaccinology
4.4.4: Market by End-Use: Pharmaceutical and Biopharmaceutical Companies and Research Institutes
4.4.5: Market by Disease: Cancer, Genetic Disorders, Infectious Diseases, and Others
4.4.6: The Chinese Viral Vector & Plasmid DNA Manufacturing Market
4.4.7: The Indian Viral Vector & Plasmid DNA Manufacturing Market
4.4.8: The Japanese Viral Vector & Plasmid DNA Manufacturing Market
4.5: ROW Viral Vector & Plasmid DNA Manufacturing Market
4.5.1: Market by Product: Viral Vector, Plasmid DNA, and Non Viral Vector,
4.5.2: Market by Workflow: Upstream Processing and Downstream Processing
4.5.3: Market by Application: Antisense & Rnai, Gene Therapy, Cell Therapy, and Vaccinology
4.5.4: Market by End-Use: Pharmaceutical and Biopharmaceutical Companies and Research Institutes
4.5.5: Market by Disease: Cancer, Genetic Disorders, Infectious Diseases, and Others
4.5.5: Brazilian Viral Vector & Plasmid DNA Manufacturing Market
5. COMPETITOR ANALYSIS
5.1: Market Share Analysis
5.2: Product Portfoli Analysis
5.3: Operational Integration
5.4: Geographical Reach
5.5: Porter’s Five Forces Analysis
6. COST STRUCTURE ANALYSIS
6.1: Cost of Goods Sold
6.2: SG&A
6.3: EBITDA Margin
7. GROWTH OPPORTUNITIES AND STRATEGIC ANALYSIS
7.1: Growth Opportunity Analysis
7.1.1: Growth Opportunities for the Global Viral Vector & Plasmid DNA Manufacturing Market by Product
7.1.2: Growth Opportunities for the Global Viral Vector & Plasmid DNA Manufacturing Market by Workflow
7.1.3: Growth Opportunities for the Global Viral Vector & Plasmid DNA Manufacturing Market by Application
7.1.4: Growth Opportunities for the Global Viral Vector & Plasmid DNA Manufacturing Market by End Use
7.1.5: Growth Opportunities for the Global Viral Vector & Plasmid DNA Manufacturing Market by Disease
7.1.6: Growth Opportunities for the Global Viral Vector & Plasmid DNA Manufacturing Market by Region
7.2: Emerging Trends in the Global Viral Vector & Plasmid DNA Manufacturing Market
7.3: Strategic Analysis
7.3.1: New Product Development
7.3.2: Capacity Expansion of the Global Viral Vector & Plasmid DNA Manufacturing Market
7.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Viral Vector & Plasmid DNA Manufacturing Market
7.3.4: Certification and Licensing
8. COMPANY PROFILES OF LEADING PLAYERS
8.1: Kaneka Eurogentec
8.2: FinVector
8.3: Brammer Bio
8.4: Cell and Gene Therapy Catapult
8.5: FUJIFILM Diosynth Biotechnologies
8.6: Sanofi
8.7: Spark Therapeutics
8.8: Cobra Biologics
8.9: UniQure
8.10: MassBiologics
2. MARKET BACKGROUND AND CLASSIFICATIONS
2.1: Introduction, Background, and Classifications
2.2: Supply Chain
2.3: Industry Drivers and Challenges
3. MARKET TRENDS AND FORECAST ANALYSIS FROM 2014 T 2025
3.1: Macroeconomic Trends and Forecast
3.2: Global Viral Vector & Plasmid DNA Manufacturing Market Trends and Forecast
3.3: Global Viral Vector & Plasmid DNA Manufacturing Market by Product
3.3.1: Viral Vector
3.3.2: Plasmid DNA
3.3.3: Non Viral Vector
3.4: Global Viral Vector & Plasmid DNA Manufacturing Market by Workflow
3.4.1: Upstream Processing
3.4.2: Downstream Processing
3.5: Global Viral Vector & Plasmid DNA Manufacturing Market by Application
3.5.1: Antisense & RNAi
3.5.2: Gene Therapy
3.5.3: Cell Therapy
3.5.4: Vaccinology Fish
3.6: Global Viral Vector & Plasmid DNA Manufacturing Market by End Use
3.6.1: Pharmaceutical and Biopharmaceutical Companies
3.6.2: Research Institutes
3.7: Global Viral Vector & Plasmid DNA Manufacturing Market by Disease
3.7.1: Cancer
3.7.2: Genetic Disorders
3.7.3: Infectious Diseases
3.7.4: Other
4. MARKET TRENDS AND FORECAST ANALYSIS BY REGION
4.1: Global Viral Vector & Plasmid DNA Manufacturing Market by Region
4.2: North American Viral Vector & Plasmid DNA Manufacturing Market
4.2.1: Market by Product: Viral Vector, Plasmid DNA, and Non Viral Vector,
4.2.2: Market by Workflow: Upstream Processing and Downstream Processing
4.2.3: Market by Application: Antisense & Rnai, Gene Therapy, Cell Therapy, and Vaccinology
4.2.4: Market by End-Use: Pharmaceutical and Biopharmaceutical Companies and Research Institutes
4.2.5: Market by Disease: Cancer, Genetic Disorders, Infectious Diseases, and Others
4.2.6: The United States Viral Vector & Plasmid DNA Manufacturing Market
4.2.7: The Canadian Viral Vector & Plasmid DNA Manufacturing Market
4.2.8: The Mexican Viral Vector & Plasmid DNA Manufacturing Market
4.3: European Viral Vector & Plasmid DNA Manufacturing Market
4.3.1: Market by Product: Viral Vector, Plasmid DNA, and Non Viral Vector,
4.3.2: Market by Workflow: Upstream Processing and Downstream Processing
4.3.3: Market by Application: Antisense & Rnai, Gene Therapy, Cell Therapy, and Vaccinology
4.3.4: Market by End-Use: Pharmaceutical and Biopharmaceutical Companies and Research Institutes
4.3.5: Market by Disease: Cancer, Genetic Disorders, Infectious Diseases, and Others
4.3.6: The United Kingdom Viral Vector & Plasmid DNA Manufacturing Market
4.3.7: The Spanish Viral Vector & Plasmid DNA Manufacturing Market
4.3.8: The German Viral Vector & Plasmid DNA Manufacturing Market
4.3.9: The French Viral Vector & Plasmid DNA Manufacturing Market
4.4: APAC Viral Vector & Plasmid DNA Manufacturing Market
4.4.1: Market by Product: Viral Vector, Plasmid DNA, and Non Viral Vector,
4.4.2: Market by Workflow: Upstream Processing and Downstream Processing
4.4.3: Market by Application: Antisense & Rnai, Gene Therapy, Cell Therapy, and Vaccinology
4.4.4: Market by End-Use: Pharmaceutical and Biopharmaceutical Companies and Research Institutes
4.4.5: Market by Disease: Cancer, Genetic Disorders, Infectious Diseases, and Others
4.4.6: The Chinese Viral Vector & Plasmid DNA Manufacturing Market
4.4.7: The Indian Viral Vector & Plasmid DNA Manufacturing Market
4.4.8: The Japanese Viral Vector & Plasmid DNA Manufacturing Market
4.5: ROW Viral Vector & Plasmid DNA Manufacturing Market
4.5.1: Market by Product: Viral Vector, Plasmid DNA, and Non Viral Vector,
4.5.2: Market by Workflow: Upstream Processing and Downstream Processing
4.5.3: Market by Application: Antisense & Rnai, Gene Therapy, Cell Therapy, and Vaccinology
4.5.4: Market by End-Use: Pharmaceutical and Biopharmaceutical Companies and Research Institutes
4.5.5: Market by Disease: Cancer, Genetic Disorders, Infectious Diseases, and Others
4.5.5: Brazilian Viral Vector & Plasmid DNA Manufacturing Market
5. COMPETITOR ANALYSIS
5.1: Market Share Analysis
5.2: Product Portfoli Analysis
5.3: Operational Integration
5.4: Geographical Reach
5.5: Porter’s Five Forces Analysis
6. COST STRUCTURE ANALYSIS
6.1: Cost of Goods Sold
6.2: SG&A
6.3: EBITDA Margin
7. GROWTH OPPORTUNITIES AND STRATEGIC ANALYSIS
7.1: Growth Opportunity Analysis
7.1.1: Growth Opportunities for the Global Viral Vector & Plasmid DNA Manufacturing Market by Product
7.1.2: Growth Opportunities for the Global Viral Vector & Plasmid DNA Manufacturing Market by Workflow
7.1.3: Growth Opportunities for the Global Viral Vector & Plasmid DNA Manufacturing Market by Application
7.1.4: Growth Opportunities for the Global Viral Vector & Plasmid DNA Manufacturing Market by End Use
7.1.5: Growth Opportunities for the Global Viral Vector & Plasmid DNA Manufacturing Market by Disease
7.1.6: Growth Opportunities for the Global Viral Vector & Plasmid DNA Manufacturing Market by Region
7.2: Emerging Trends in the Global Viral Vector & Plasmid DNA Manufacturing Market
7.3: Strategic Analysis
7.3.1: New Product Development
7.3.2: Capacity Expansion of the Global Viral Vector & Plasmid DNA Manufacturing Market
7.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Viral Vector & Plasmid DNA Manufacturing Market
7.3.4: Certification and Licensing
8. COMPANY PROFILES OF LEADING PLAYERS
8.1: Kaneka Eurogentec
8.2: FinVector
8.3: Brammer Bio
8.4: Cell and Gene Therapy Catapult
8.5: FUJIFILM Diosynth Biotechnologies
8.6: Sanofi
8.7: Spark Therapeutics
8.8: Cobra Biologics
8.9: UniQure
8.10: MassBiologics
